Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RET Gene Mutation”

21 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 21 results

Testing effectiveness (Phase 2)Looking for participantsNCT06109558
What this trial is testing

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Who this might be right for
Non Small Cell Lung CancerRET Gene MutationMET Amplification+1 more
Hunan Province Tumor Hospital 120
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Early research (Phase 1)Study completedNCT01531361
What this trial is testing

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Who this might be right for
Advanced Malignant NeoplasmBRAF Gene MutationMetastatic Malignant Neoplasm+2 more
M.D. Anderson Cancer Center 46
Not applicableNot Yet RecruitingNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03157128
What this trial is testing

Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+1 more
Eli Lilly and Company 857
Testing effectiveness (Phase 2)Study completedNCT01813734
What this trial is testing

Ponatinib in Advanced NSCLC w/ RET Translocations

Who this might be right for
Non Small Cell Lung Cancer
Massachusetts General Hospital 9
Testing effectiveness (Phase 2)Study completedNCT01831726
What this trial is testing

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Who this might be right for
Tumor Pathway Activations Inhibited by Dovitinib
Novartis Pharmaceuticals 80
Testing effectiveness (Phase 2)Study completedNCT02272998
What this trial is testing

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Who this might be right for
Malignant Neoplasm
Sameek Roychowdhury 22
Early research (Phase 1)Study completedNCT01877811
What this trial is testing

Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors

Who this might be right for
Solid Tumors
Hoffmann-La Roche 143
Not applicableNot Yet RecruitingNCT07042984
What this trial is testing

RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer

Who this might be right for
Papillary Thyroid CarcinomaThyroid NeoplasmsRET Proto-Oncogene Mutation+1 more
Fujian Medical University 800
Early research (Phase 1)Study completedNCT03784378
What this trial is testing

Continued Access to RXDX-105

Who this might be right for
Non Small Cell Lung CancerOvarian CancerRET Gene Mutation+1 more
Memorial Sloan Kettering Cancer Center 3
Testing effectiveness (Phase 2)Looking for participantsNCT05800340
What this trial is testing

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Who this might be right for
Non-Small Cell Lung CancerRET Driver MutationBRAF V600 Mutation+3 more
Guangdong Provincial People's Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05675605
What this trial is testing

TY-1091 in Patients With Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+1 more
TYK Medicines, Inc 248
Not applicableStudy completedNCT01945762
What this trial is testing

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

Who this might be right for
Symptomatic, Aggressive, Sporadic, Unresectable, LocallyAdvanced/Metastatic Medullary Thyroid Cancer (MTC)
Genzyme, a Sanofi Company 31
Testing effectiveness (Phase 2)Ended earlyNCT04161391
What this trial is testing

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Who this might be right for
Non Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more
Turning Point Therapeutics, Inc. 41
Large-scale testing (Phase 3)Study completedNCT04222972
What this trial is testing

Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell Lung+14 more
Hoffmann-La Roche 223
Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Not applicableNot Yet RecruitingNCT07048964
What this trial is testing

A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations

Who this might be right for
Medullary Thyroid Cancer (MTC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03899792
What this trial is testing

Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Who this might be right for
Medullary Thyroid CancerInfantile MyofibromatosisInfantile Fibrosarcoma+2 more
Eli Lilly and Company 36
Load More Results